Supplementary Tables S1-S10 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma

Le résumé fourni par la source

Supplementary Table S1: Overview of Antibodies Used for Flow Cytometry and Phenotyping. Supplementary Table S2: Overview of Antibodies Used for the Co-culture Assays and Intracellular Cytokine Staining Supplementary Table S3: Baseline Characteristics and Clinical Response Data Supplementary Table S4: Phenotypic Composition of the infused TIL-IMP (% of parent with IQR) Supplementary Table S5: Absolute numbers of TIL-IMP subsets infused (median cell count with IQR) Supplementary Table S6: Absolute number of TIL-IMP, CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS. Supplementary Table S7: Frequency of CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS Supplementary Table S8: Baseline characteristics of patients included in the functional sub-analysis Supplementary Table S9: Comparison of baseline characteristics for patients with and without autologous TCLs Supplementary Table S10: Comparison of baseline characteristics for patients with high and low baseline MTV

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.